Scarica l'app Stockscreener
13.97
0.54%
-0.08
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Perché RDY Giù?
Forum
Previsione
Frazionamento azionario
Storia dei dividendi
Precedente Chiudi:
$14.05
Aprire:
$14.03
Volume 24 ore:
307.11K
Relative Volume:
0.31
Capitalizzazione di mercato:
$11.67B
Reddito:
$3.85B
Utile/perdita netta:
$667.93M
Rapporto P/E:
21.26
EPS:
0.657
Flusso di cassa netto:
$142.30M
1 W Prestazione:
+0.75%
1M Prestazione:
-5.26%
6M Prestazione:
-3.63%
1 anno Prestazione:
-2.28%
Intervallo 1D:
$13.92
$14.08
Intervallo di 1 settimana:
$13.71
$14.10
Portata 52W:
$12.26
$16.17
Dr Reddys Laboratories Ltd Adr Stock (RDY) Company Profile
Confronta RDY con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
RDY
Dr Reddys Laboratories Ltd Adr
|
13.98 | 11.70B | 3.85B | 667.93M | 142.30M | 0.657 |
|
ZTS
Zoetis Inc
|
116.33 | 51.60B | 9.40B | 2.65B | 2.24B | 5.935 |
|
TAK
Takeda Pharmaceutical Co Adr
|
14.06 | 44.51B | 29.63B | 260.53M | 5.51B | 0.0788 |
|
HLN
Haleon Plc Adr
|
9.625 | 42.35B | 14.26B | 1.98B | 2.47B | 0.4327 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
24.30 | 28.04B | 16.70B | -157.13M | 1.19B | -0.1446 |
|
UTHR
United Therapeutics Corp
|
474.74 | 20.52B | 3.08B | 1.24B | 1.07B | 25.61 |
Dr Reddys Laboratories Ltd Adr Stock (RDY) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-06-05 | Aggiornamento | HSBC Securities | Hold → Buy |
| 2024-12-19 | Downgrade | Nomura | Buy → Neutral |
| 2024-01-11 | Downgrade | Jefferies | Buy → Underperform |
| 2023-08-29 | Downgrade | HSBC Securities | Buy → Hold |
| 2023-05-18 | Downgrade | Bernstein | Outperform → Mkt Perform |
| 2023-03-17 | Aggiornamento | BofA Securities | Neutral → Buy |
| 2023-01-30 | Iniziato | JP Morgan | Underweight |
| 2022-11-14 | Downgrade | Credit Suisse | Neutral → Underperform |
| 2022-01-03 | Ripresa | BofA Securities | Neutral |
| 2021-07-27 | Downgrade | Credit Suisse | Outperform → Neutral |
| 2021-02-02 | Aggiornamento | Barclays | Equal Weight → Overweight |
| 2020-09-18 | Aggiornamento | BofA Securities | Neutral → Buy |
| 2020-09-18 | Aggiornamento | Investec | Sell → Hold |
| 2020-01-28 | Downgrade | CLSA | Buy → Outperform |
| 2020-01-27 | Downgrade | CLSA | Buy → Outperform |
| 2020-01-09 | Aggiornamento | Citigroup | Sell → Buy |
| 2019-11-04 | Downgrade | BofA/Merrill | Buy → Neutral |
| 2019-09-04 | Aggiornamento | Credit Suisse | Underperform → Outperform |
| 2019-07-01 | Aggiornamento | Macquarie | Neutral → Outperform |
| 2019-06-20 | Iniziato | Deutsche Bank | Hold |
| 2019-06-11 | Iniziato | Barclays | Equal Weight |
| 2019-05-20 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| 2019-02-19 | Aggiornamento | CLSA | Outperform → Buy |
| 2019-01-17 | Downgrade | Citigroup | Neutral → Sell |
| 2017-09-21 | Aggiornamento | Morgan Stanley | Equal-Weight → Overweight |
| 2017-08-31 | Aggiornamento | CLSA | Underperform → Outperform |
| 2017-07-28 | Downgrade | CLSA | Underperform → Sell |
| 2016-07-27 | Downgrade | HSBC Securities | Hold → Reduce |
| 2016-07-27 | Downgrade | Jefferies | Hold → Underperform |
| 2016-02-10 | Aggiornamento | Credit Agricole | Underperform → Buy |
| 2015-11-10 | Downgrade | Citigroup | Buy → Neutral |
Mostra tutto
Dr Reddys Laboratories Ltd Adr Borsa (RDY) Ultime notizie
Apple Upgraded, DraftKings Downgraded: Updated Rankings on Top Blue-Chip Stocks - InvestorPlace
Fintech ADRs Dropped While Telecoms And Pharma Firmed Up - Finimize
Dr Reddy's ADR Slumps 10% After Bid To Launch Weight-Loss Drug In Canada Hits Regulatory Hurdle - MSN
L&T, Dr Reddys Labs, Coal India, Varun Beverages — Check Price Target Changes From Analysts - NDTV Profit
Why Dr Reddy’s stock may fall today; buzzing stocks list - BusinessLine
Indian pharma giant says Health Canada rejected its application to make generic semaglutide - The Globe and Mail
Asian ADRs See Mixed Results With Fintech In Focus - Finimize
Dr Reddys ADR Slumps 10% After Bid To Launch Weight-Loss Drug In Canada Hits Regulatory Hurdle - NDTV Profit
Dr. Reddy's Laboratories Ltd $RDY Shares Sold by Logan Capital Management Inc. - MarketBeat
Asian Stocks See Gains In US Trading This Week - Finimize
Dr. Reddy’s Labs ADR earnings beat, revenue topped estimates By Investing.com - Investing.com Nigeria
Dr. Reddy’s Labs ADR earnings beat, revenue topped estimates - Investing.com
Dr. Reddy's Earnings: Solid Growth Seen, Despite Softness in US, Thanks to Growing European Presence - Morningstar
Asian ADRs Kept Steady As Investors Pick Favorites - Finimize
Asian Stocks Climb In The US As Big Names Rally - Finimize
Infosys Q2 results out! Here’s what experts, Infosys ADR signal about stock price - Mint
Asian ADRs Stay Calm As Individual Stocks Swing Both Ways - Finimize
Dr. Reddy's Laboratories Ltd Common Stock (NY: - FinancialContent
Asian Stocks In The US Closed Lower This Week - Finimize
Full Truck Alliance Co. Ltd. Sponsored ADR $YMM Shares Purchased by Mirae Asset Global Investments Co. Ltd. - Defense World
Corporacion Inmobiliaria Vesta, S.A.B. de C.V. Sponsored ADR (NYSE:VTMX) Receives $31.33 Consensus Target Price from Analysts - Defense World
Cash per share of Dr. Reddy's Laboratories Ltd. Sponsored ADR – NYSE:RDY - TradingView
Teva, Viatris On Investor Watch As White House Spares Generic Drugs From Tariffs - Benzinga
Teva, Viatris On Investor Watch As White House Spares Generic Drugs From Tariffs - Sahm
HB Wealth Management LLC Takes $181,000 Position in Dr. Reddy’s Laboratories Ltd $RDY - Defense World
Robeco Institutional Asset Management B.V. Buys 1,452,192 Shares of Dr. Reddy's Laboratories Ltd $RDY - MarketBeat
Asian ADRs Rise As Regional Firms Show Mixed Performance - Finimize
Dr Reddys Laboratories Ltd Adr Azioni (RDY) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
2.11%
0.94%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):